Company Active LTD

Company profile

Cell Therapy Catapult Services Limited

UK company 08215513, incorporated on 14 September 2012.

Advancing cell and gene therapies through powerful collaborations - Cell and Gene Therapy

Cell Therapy Catapult Services Limited is a UK company with status Active founded in 2012 based in London.

Company number
08215513
Incorporated
14 Sep 2012
Companies House status
Active

Company identity

Founded / incorporated
14 September 2012

Company number 08215513

Verify at Companies House
Legal name
CELL THERAPY CATAPULT SERVICES LIMITED
Company type
Private Limited Company
Region
London
Registered address
12TH FLOOR TOWER WING B
GUYS HOSPITAL
LONDON
SE1 9RT
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Cell Therapy Catapult Services Limited
CRN 08215513
2
Direct and ultimate controller Active PRIVATE-LIMITED-GUARANT-NSC

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

27 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

13 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

14 Sep
2012

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2020
Funded years
2020, 2024
Age at first award
7 years

Projects

2024 Collaborative R&D Lead participant

Next-generation automation and PAT implementation for QbD and enhanced approaches for cell and gene therapy

1 Feb 2024 to 31 Jan 2026

Awarded
£398,677
Total cost £577,291

The therapeutic potential for cell and gene therapies is immense, with treatments approved for previously intractable diseases. (e.g. Kymriah for blood cancers, Zolgensma for spinal muscular atrophy, and Luxturna for inherited retinal dystrophy) However, the price remains prohibitively high. Limiting patient access to relatively rare indications or narrow...

2020 CR&D Bilateral

Assessing PAT for process monitoring and modification of viral vector manufacture processing

1 Mar 2020 to 30 Nov 2021

Awarded
£0
Total cost £283,518

This project is aligned with the scope of the "Mechanising and Improving Advanced Therapy Manufacture" competition. Specifically, the project will address challenges in the manufacture of AAV gene therapies and will establish Allergan's UK-based 200-strong workforce as a key player within the AAV industry improving the competitiveness and productivity of ...

Product types

Collaborative R&D CR&D Bilateral